|1.||Motzer, Robert J: 48 articles (01/2016 - 01/2006)|
|2.||Rini, Brian I: 44 articles (12/2015 - 12/2005)|
|3.||Raymond, Eric: 27 articles (04/2015 - 01/2006)|
|4.||Choueiri, Toni K: 23 articles (10/2015 - 01/2008)|
|5.||Hutson, Thomas E: 23 articles (12/2014 - 01/2007)|
|6.||Szczylik, Cezary: 21 articles (10/2015 - 01/2007)|
|7.||Huang, Xin: 21 articles (11/2014 - 10/2007)|
|8.||Michaelson, M Dror: 20 articles (12/2015 - 01/2006)|
|9.||Faivre, Sandrine: 20 articles (04/2015 - 01/2006)|
|10.||Porta, Camillo: 19 articles (01/2015 - 08/2008)|
|1.||Renal Cell Carcinoma (Grawitz Tumor)
04/01/2015 - "We report a case of poor-risk metastatic renal cell carcinoma, with Von Hippel-Lindau loss of function, which achieved and maintained a complete remission after first-line therapy with sunitinib by using a reduced dosage and a modified schedule of treatment. "
04/01/2015 - "Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy."
12/01/2014 - "We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. "
09/01/2011 - "We report a case with a complete pathology-proven remission after sunitinib treatment of a relapsed irresectable clear cell renal carcinoma. "
09/01/2014 - "In a randomized Phase III trial of treatment-naive patients with metastatic renal cell carcinoma (mRCC), patients treated with sunitinib showed a significant improvement in progression-free survival compared with those treated with IFN-α. "
05/01/2015 - "In vivo, administration of sunitinib induced the significantly marked growth inhibition of PC3/sh-Akt1 compared with that of PC3/C, and apoptotic index in PC3/sh-Akt1 tumor in mice treated with sunitinib was significantly greater than that in PC3/C tumor. "
08/01/2009 - "Sunitinib has proven efficacy in the management of metastatic RCC (mRCC), however, there is very limited evidence of primary tumor response. "
05/01/2006 - "Thus, the potent efficacy of SU11248 in models representing diverse signaling paradigms results from simultaneous inhibition of individual target receptors expressed both in cancer cells and in the tumor neovasculature, supporting the hypothesis that multitargeted inhibitors have the cumulative antitumor efficacy of combined single-target inhibitors."
10/01/2011 - "Sunitinib was also associated with a significantly greater objective tumor response rate than placebo, although limited data from an updated analysis demonstrated no significant difference between the treatments groups in terms of median overall survival. "
04/15/2008 - "Sunitinib can induce a significant reduction in volume of primary renal cell tumors. "
|3.||Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
06/01/2013 - "Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience."
11/01/2015 - "Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor."
05/01/2015 - "Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib."
10/01/2014 - "Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study."
10/01/2010 - "The aim of this review is to gather the preclinical rationale behind the clinical use of sunitinib in gastrointestinal malignancies other than gastrointestinal stromal tumors (GIST) and to summarize the clinical data from phase I to III trials currently available."
|4.||Kidney Neoplasms (Kidney Cancer)
01/01/2010 - "The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer."
11/01/2015 - "Kidney cancer: Sunitinib: 2/1 is superior to 4/2."
01/01/2008 - "Sunitinib is widely used as first-line treatment for metastatic clear cell renal cancer (MCRC). "
01/01/2012 - "The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer."
01/01/2014 - "Sunitinib is the first-line treatment for renal cancer and we report a case of a man receiving this medication who also had diabetes. "
|5.||Neoplasm Metastasis (Metastasis)
12/01/2009 - "Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases."
12/01/2010 - "Results suggest targeted agents such as sunitinib may be an effective treatment for bone metastases."
06/01/2009 - "Sunitinib is effective in patients with pancreatic metastasis. "
09/01/2015 - "Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases."
08/01/2015 - "Overall survival from treatment initiation (OSinitiation), overall survival from the first documented metastasis (OStotal), and progression-free survival (PFS) were similar for patients who received first-line sunitinib for conventional relative to attenuated dose regimens (OSinitiation: 18.3 vs. 16.5 months, respectively; P = .54; OStotal: 27.4 vs. 21.8 months, respectively; P = .45; PFS: 6.7 vs. 7.9 months, respectively; P = .64), similar to real-world outcomes in Western studies. "
|1.||sorafenib (BAY 43-9006)
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|7.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Interferon-alpha (Interferon Alfa)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)